Laboratoire des Pathogènes Emergents, Fondation Mérieux, 21 avenue T Garnier, 69007 Lyon, France.
J Clin Microbiol. 2010 Nov;48(11):4207-15. doi: 10.1128/JCM.00344-10. Epub 2010 Sep 8.
Genome analysis of hepatitis B virus (HBV) in patient sera is helpful for monitoring treatment. We developed an improved version of a DNA microarray to identify HBV genotypes and to detect mutations of interest in the S, Pol, Core, and X genes. It includes an automated software analysis of fluorescence values for simpler, more robust data interpretation. In this version, probes were added to identify genotype H, to analyze 155 additional positions, and to detect 561 additional polymorphisms. Sequences were added to the alignments to resolve hybridization problems due to natural polymorphisms in the vicinity of important codons. The duplex PCR protocol allowed whole-genome analysis in a single tube. An alternative nested-PCR protocol allowed genotyping and mutations in S and reverse transcriptase (rt) genes in patients with low viral loads, as demonstrated in patients with less than 400 HBV genome copies/ml. Reproducibility was high, with variation coefficients lower than 3%. Only 0.57% of 20,771 codons from 253 samples could not be identified. The concordance with Sanger sequencing for the identification of codons improved from 92.8% to 95.7% with the improved version. Concordance was higher than 91% for codons associated with resistance to lamivudine, emtricitabine, telbivudine, famciclovir, entecavir, and tenofovir with vaccine escape and for pre-Core mutants. Concordance was lower for adefovir resistance mutations (68.6%) and mutations in the basal core promoter (60.3%), probably because hybridization efficiency was affected by the low GC content of the probes. A concordance of 93.7% with sequencing for genotype identification was observed in 190 specimens, lower than that obtained with the first version, possibly due to mixed virus populations.
对乙型肝炎病毒(HBV)患者血清中的基因组进行分析有助于监测治疗。我们开发了一种 DNA 微阵列的改进版本,用于鉴定 HBV 基因型,并检测 S、Pol、Core 和 X 基因中感兴趣的突变。它包括荧光值的自动软件分析,以实现更简单、更稳健的数据解释。在这个版本中,添加了探针来鉴定基因型 H,分析 155 个额外的位置,并检测 561 个额外的多态性。在邻近重要密码子的附近,由于自然多态性的存在,会出现杂交问题,因此在序列中添加了序列来解决这些问题。该双 PCR 方案允许在单个管中进行全基因组分析。替代的嵌套 PCR 方案允许对低病毒载量患者的 S 和逆转录酶(rt)基因进行基因分型和突变,如在 HBV 基因组拷贝/ml 小于 400 的患者中所证明的那样。重复性很高,变异系数低于 3%。在 253 个样本的 20771 个密码子中,只有 0.57%无法识别。改进后的版本提高了与 Sanger 测序在鉴定密码子方面的一致性,从 92.8%提高到 95.7%。对于与拉米夫定、恩曲他滨、替比夫定、泛昔洛韦、恩替卡韦和替诺福韦耐药、疫苗逃逸以及前核心突变相关的密码子,一致性高于 91%。阿德福韦耐药突变(68.6%)和基本核心启动子突变(60.3%)的一致性较低,这可能是由于杂交效率受到探针低 GC 含量的影响。在 190 个标本中观察到与测序的基因型鉴定的一致性为 93.7%,低于第一个版本,这可能是由于病毒混合种群。